Cargando…

Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) have become significant global health concerns. In the present study, we aimed to investigate the effects of saroglitazar, a dual PPARα/γ agonist, fenofibrate, a PPAR-α agonist, and pioglitazone, a PPAR-γ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akbari, Rasoul, Behdarvand, Tahereh, Afarin, Reza, Yaghooti, Hamid, Jalali, Mohammad Taha, Mohammadtaghvaei, Narges
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485507/ https://www.ncbi.nlm.nih.gov/pubmed/34593018 http://dx.doi.org/10.1186/s40360-021-00524-8

Ejemplares similares

Capparis spinosa improves the high fat diet-induced non-alcoholic steatohepatitis in rats: the possible role of FGF21
por: Akbari, Rasoul, et al.
Publicado: (2020)

Capparis spinosa improves non-alcoholic steatohepatitis through down-regulating SREBP-1c and a PPARα-independent pathway in high-fat diet-fed rats
por: Akbari, Rasoul, et al.
Publicado: (2022)

The efficacy of calcitriol treatment in non-alcoholic fatty liver patients with different genotypes of vitamin D receptor FokI polymorphism
por: Yaghooti, Hamid, et al.
Publicado: (2021)

Exosomes of Whartons’ jelly mesenchymal stem cell reduce the NOX genes in TGF-β-induced hepatic fibrosis
por: Afarin, Reza, et al.
Publicado: (2022)

The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease
por: Kumar, Divya P., et al.
Publicado: (2020)

Isorhamnetin Alleviates Steatosis and Fibrosis in Mice with Nonalcoholic Steatohepatitis
por: Ganbold, Munkhzul, et al.
Publicado: (2019)

Steatosis and Steatohepatitis: Complex Disorders
por: Bettermann, Kira, et al.
Publicado: (2014)

Significant Reduction of Elevated Triglycerides and Liver Fibrosis in Diabetic Dyslipidemia with Saroglitazar: A Case Report
por: Roy, Sayak, et al.
Publicado: (2019)

Association between the rs615563 variant of PCSK9 gene and circulating lipids and Type 2 diabetes
por: Taghizadeh Jazdani, Samira, et al.
Publicado: (2021)

Saroglitazar – A Potential Therapeutic Option in Treating NASH? [Letter]
por: Shuja, Syed Hasan, et al.
Publicado: (2021)

Steatosis, Steatohepatitis and Cancer Immunotherapy: An Intricate Story
por: Cataldi, Mauro, et al.
Publicado: (2021)

Berberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress
por: Zhang, Zhiguo, et al.
Publicado: (2016)

Treatment with Oxidized Phospholipids Directly Inhibits Nonalcoholic Steatohepatitis and Liver Fibrosis Without Affecting Steatosis
por: Mendel, Itzhak, et al.
Publicado: (2016)

Liver sphingomyelin synthase 1 deficiency causes steatosis, steatohepatitis, fibrosis, and tumorigenesis: An effect of glucosylceramide accumulation
por: Li, Zhiqiang, et al.
Publicado: (2021)

β-Hydroxyphosphocarnitine modifies fibrosis, steatosis and improves liver function in non-alcoholic steatohepatitis induced in rats
por: Sánchez-Quevedo, Janet, et al.
Publicado: (2022)

The Role of Lipid Profile as an Independent Predictor of Non-alcoholic Steatosis and Steatohepatitis in Morbidly Obese Patients
por: Ganjooei, Narges Ashraf, et al.
Publicado: (2021)

Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidence
por: Sosale, Aravind, et al.
Publicado: (2015)

Associations of circulating chemerin and adiponectin concentrations with hepatic steatosis
por: Levin, Lena-Maria, et al.
Publicado: (2019)

Role of antioxidant property of carvedilol in mild to moderate hypertensive patients: A prospective open-label study
por: Ayashi, Saleh, et al.
Publicado: (2016)

Animal Models of Steatosis (NAFLD) and Steatohepatitis (NASH) Exhibit Hepatic Lobe-Specific Gelatinases Activity and Oxidative Stress
por: Palladini, Giuseppina, et al.
Publicado: (2019)

Differential Intrahepatic Phospholipid Zonation in Simple Steatosis and Nonalcoholic Steatohepatitis
por: Wattacheril, Julia, et al.
Publicado: (2013)

Analysis of miRNAs Profiles in Serum of Patients With Steatosis and Steatohepatitis
por: Vulf, Maria, et al.
Publicado: (2021)

Deciphering the Precise Target for Saroglitazar Associated Antiangiogenic Effect: A Computational Synergistic Approach
por: Dabral, Swarna, et al.
Publicado: (2023)

MicroRNA-155 Deficiency Attenuates Liver Steatosis and Fibrosis without Reducing Inflammation in a Mouse Model of Steatohepatitis
por: Csak, Timea, et al.
Publicado: (2015)

Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis
por: Sebastiani, Giada, et al.
Publicado: (2015)

Sarcopoterium spinosum Inhibited the Development of Non-Alcoholic Steatosis and Steatohepatitis in Mice
por: Wollman, Ayala, et al.
Publicado: (2019)

CCN1 promotes hepatic steatosis and inflammation in non-alcoholic steatohepatitis
por: Ju, Linling, et al.
Publicado: (2020)

Observational Study of Effects of Saroglitazar on Glycaemic and Lipid Parameters on Indian Patients with Type 2 Diabetes
por: Chatterjee, Sanjay, et al.
Publicado: (2015)

Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial
por: Rodriguez-Gutierrez, Rene, et al.
Publicado: (2022)

Efficacy and safety of saroglitazar for the management of dyslipidemia: A systematic review and meta-analysis of interventional studies
por: Chhabra, Manik, et al.
Publicado: (2022)

Adiponectin in renal fibrosis
por: Jing, Huan, et al.
Publicado: (2020)

Type 2 Diabetes Mellitus Coincident with Clinical and Subclinical Thyroid Dysfunctions Results in Dysregulation of Circulating Chemerin, Resistin and Visfatin
por: Tabandeh, Mohammad Reza, et al.
Publicado: (2023)

Adiponectin and Its Receptors in Chronic Hepatitis B Patients With Steatosis in China
por: Wu, Di, et al.
Publicado: (2013)

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
por: Jain, Mukul R., et al.
Publicado: (2017)

Fermented ginseng, GBCK25, ameliorates steatosis and inflammation in nonalcoholic steatohepatitis model
por: Choi, Naeun, et al.
Publicado: (2019)

Steatosis and steatohepatitis found in adults after death due to non-burn trauma
por: Reis-Júnior, Paulo, et al.
Publicado: (2019)

Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review
por: Pan, Chelsea S., et al.
Publicado: (2020)

Integration analysis identifies the role of metallothionein in the progression from hepatic steatosis to steatohepatitis
por: Li, Xiaoya, et al.
Publicado: (2022)

Gene Expression Profiling Unravels Cancer-Related Hepatic Molecular Signatures in Steatohepatitis but Not in Steatosis
por: Starmann, Julia, et al.
Publicado: (2012)

The Differential Expression of Cide Family Members is Associated with Nafld Progression from Steatosis to Steatohepatitis
por: Sans, Arnaud, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nganfk2uks19j3cm1vnq3ehh7g